We specialize in creating precise investment opportunities in the biotechnology space. Our first ETF, CNCR, focuses on the transformational field of cancer immunotherapy. It tracks the Loncar Cancer Immunotherapy Index.
About Our ETF
Precise Investment Opportunities
Biotechnology innovation matters. Whether it is a cure for hepatitis C, new advances in cancer care, or progress against rare and debilitating diseases like cystic fibrosis, patients around the world are benefiting from unprecedented innovation that the biotech industry is delivering.
Much of this can be attributed to precision medicine. As the practice of medicine has advanced, it has also become more precise. Genetic sequencing and a greater understanding of disease at the cellular and molecular level has allowed researchers to target an area of focus with precision.
Our ETF takes the same approach to investing. We specialize in creating precise investment opportunities that more closely match specific investor interests. Whether it be supporting cancer research or another area of focus, our approach is to deliver with specificity what investors are looking for.
Dedicated to Making an Impact
Our ETF is dedicated to making an impact. Biotechnology encompasses dozens of different business models, but not all represent high innovation. We aim to invest in those technologies that are pushing medicine forward and have the biggest impact on patients’ lives.
Our first ETF, the Loncar Cancer Immunotherapy ETF, tracks the Loncar Cancer Immunotherapy Index and focuses on the transformational field of cancer immunotherapy.
By harnessing the immune system and rethinking how to approach the disease, innovative immunotherapy companies are making a difference for courageous patients who battle cancer. We are proud to support this important work and its positive impact on our society.